Relay Therapeutics, Inc.
Relay Therapeutics is a clinical-stage small-molecule precision medicine company developing therapies for patients with cancer and genetic diseases. Its Dynamo platform combines computational and experimental approaches to study protein motion and identify potential drug targets. Relay uses the platform to discover and develop product candidates, with programs in precision oncology and genetic disease. Its lead candidate, zovegalisib, is being evaluated for PI3Kα-mutated breast cancer and vascular anomalies. Other programs include the NRAS-selective inhibitor RLY-8161, a non-inhibitory chaperone for Fabry disease and early-stage discovery programs. Relay has granted Elevar Therapeutics global development and commercialization rights to lirafugratinib, while retaining full development and commercialization rights to its other active precision medicine programs. It is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Jones Trading reaffirmed its Buy rating for Relay Therapeutics and increased its price target to $31 from $20, citing a 66.7% upside from the Nov 6 close of $18.60.
Relay Therapeutics, Inc.'s average stock price target was reduced from $27.58 to $27.42 by 12 analysts, with a range of $20 to $32. This implies a 52% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 13 analysts.
Relay Therapeutics reported Q3 GAAP EPS of -$0.37, exceeding expectations by $0.03. The company had $848.6M in cash and investments as of September 30, 2026, down from $910.9M in June 2026. The article also mentions recent market excitement and clinical risks.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RLAY (Relay Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RLAY coverage spans financial news, insider activity and earnings.
In the last 30 days, RLAY insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($83K). The most active reporter was Rahmer Peter, See remarks, with 1 filing.
Analyst upgrade suggests potential upside for the stock.
The target reduction signals a modest downgrade, likely capping upside momentum.
Earnings beat on a loss may limit upside; investors may view the modest beat as insufficient to drive price higher.
FDA approval and strong cash position are likely to lift the stock.
Analyst upgrade to Buy with a higher price target.
AlphAI scores every news story that mentions RLAY with an AI model for sentiment and relevance, and aggregates insider trades from Relay Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jones Trading reaffirmed its Buy rating for Relay Therapeutics and increased its price target to $31 from $20, citing a 66.7% upside from the Nov 6 close of $18.60.
Relay Therapeutics, Inc.'s average stock price target was reduced from $27.58 to $27.42 by 12 analysts, with a range of $20 to $32. This implies a 52% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 13 analysts.
Relay Therapeutics reported Q3 GAAP EPS of -$0.37, exceeding expectations by $0.03. The company had $848.6M in cash and investments as of September 30, 2026, down from $910.9M in June 2026. The article also mentions recent market excitement and clinical risks.
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies t
Analysts maintained Buy ratings on Relay Therapeutics (RLAY), Boston Scientific (BSX), and Palisade Bio (PALI). Price targets set at $25 for RLAY, $66 for BSX, and $7 for PALI. All three have Strong Buy consensus ratings.
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.10 ($0.87M total) on 2026-10-07 under a Rule 10b5-1 trading plan.
Relay Therapeutics (RLAY) is discussed as potentially 35% undervalued, contingent on successful trials of zovegalisib for breast cancer. The article also highlights areas of concern for investors to consider. Simply Wall St notes that the analysis is based on historical data and forecasts, not financial advice.
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.94 ($0.91M total) on 2026-09-08 under a Rule 10b5-1 trading plan.
On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%
SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).
